The post-hoc analysis sought to identify factors predictive of relapse and disability progression in people with MS enrolled in the TRANSFORMS study.
Researchers sought to determine whether treatment with ocrelizumab improved measures of cognitive function better than interferon beta 1-a.
Initial trials of teriflunomide have demonstrated low lymphocyte counts in patients with relapsing forms of MS.
In patients with MS, hand function often correlates with measures of quality of life.
The prevalence of osteoporosis was greater in patients with MS than in matched controls.
Cognitive fatigue and anxiety are common symptoms reported by patients with multiple sclerosis.
Boys with onset of MS during puberty experienced an increased rate of relapse compared with boys with MS onset before or after puberty.
Radicava is the first approved treatment for ALS in over 20 years.
More accurate prediction of ALS prognosis can allow for better planned palliative care.
Longer studies are needed to further evaluate the effect of vitamin D supplementation on cognition in multiple sclerosis.
Increased risk of pediatric multiple sclerosis was observed in patients with prior exposure to EBV, HSV-1, and vitamin D deficiency.
In older patients with relapsing multiple sclerosis, patient-reported fatigue and problems with lower extremities may signal conversion to secondary progressive disease.
More participants achieved clinical NEDA with DMF than placebo over 2 years in the integrated analysis.
The biannual infusion is approved for the treatment of adults with relapsing and progressive forms of multiple sclerosis.
A study aimed to clarify the relationship between anxiety and depression in patients with multiple sclerosis.
Mindfulness meditation was associated with improvements in measures of anxiety, depression, and negative thoughts.
Opicinumab may potentially enhance spontaneous remyelination after acute optic neuritis.
Emflaza is approved for the treatment of Duchenne muscular dystrophy regardless of genetic etiology.
Several new multiple sclerosis drugs, including natalizumab, may be more effective at reducing relapses but still come with serious safety concerns.
Five years after treatment, nearly 70% of patients with relapsing-remitting multiple sclerosis showed no signs of disease progression.
Several microRNA were found to be associated with lesion volume and brain atrophy in multiple sclerosis.
Despite an elevated risk of PML, treatment with natalizumab results in slower disease progression than other treatments.
Patients with both MS and epileptic seizures had a younger age at onset of MS compared with those without seizures.
Researchers report 2 cases of a severe B-cell-mediated CNS disease after treatment with alemtuzumab in patients with multiple sclerosis.
Soliris is currently approved to treat paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS).
More structured MRI reports may aid in the diagnosis of multiple sclerosis.
It is not clear whether CSF CD27 could provide novel or simply complementary prognostic value in clinically isolated syndrome.
The US FDA has approved the first drug for the treatment of spinal muscular atrophy, a genetic disease that often results in premature death.
Patients who received ACE inhibitors showed a slower progression of myocardial fibrosis and fewer cardiovascular events.
Low levels of neonatal vitamin D may be linked with risk of developing multiple sclerosis.
Neurology Advisor Articles
- Vitamin D Deficiency Affects Cognition in Multiple Sclerosis
- Telestroke Treatment With IV tPA: How Long Is the Window of Opportunity?
- Hypothalamus May Play a Central Role in Chronic Migraine
- Migraine Attacks Associated With Reduced Dopamine Levels
- Polypharmacy in Schizophrenia May Have Adverse Effect on Cognition
- In MS, Disease Duration, Lesion Load Predict Relapses and Disability Progression
- Ocrelizumab May Improve Cognitive Function in Relapsing Multiple Sclerosis
- Teriflunomide for MS Associated With Low Rates of Infection, Lymphopenia
- The Handoff: Your Week in Neurology News - 5/25/17
- In Multiple Sclerosis, Hand Strength May Indicate Disease Status